Tin-Yun Tang, MD
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2017 | Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, US, Medicine, Doctor of Medicine |
| 2011 | University of California, San Diego, San Diego, California, US, Bachelor of Science |
Postgraduate Training
| 2021-2024 | Clinical Fellow, Hematology and Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2018-2021 | Resident, Internal Medicine-Medical Genetics and Genomics, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, Ohio |
| 2017-2018 | Intern, Internal Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, Ohio |
| 2014-2015 | HHMI Medical Research Fellow, Gene Therapy, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania |
Licenses & Certifications
| 2024 | Medical Oncology |
| 2021 | Internal Medicine, American Board of Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Department Lead for Palantir Foundry Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
HHMI Medical Fellows Northeast Regional Co-Chair, Howard Hughes Medical Institute, Philadelphia, Pennsylvania, 2014 - 2015
Intramural Institutional Committee Activities
Member, Scientific Review Committee 4, The University of Texas MD Anderson Cancer Center, 2025 - Present
Peer Elected Representative for Medical Genetics, Resident Forum, University Hospitals Cleveland Medical Center, 2019 - 2021
Honors & Awards
| 2024 | 2024 Leading Clinical Research Faculty Learning Series, MD Anderson Cancer Center |
| 2023 | 2023-2024 FDA-AACR Oncology Educational Fellowship, FDA and AACR |
| 2023 | 2023 ASCO/AACR Methods in Clinical Cancer Research, ASCO and AACR |
| 2023 | Poster Honorable Mention, Cholangiocarcinoma Foundation |
| 2022 | 2023 Conquer Cancer Merit Award, Conquer Cancer, the ASCO Foundation |
| 2022 | 2022 Conquer Cancer Merit Award, Conquer Cancer, the ASCO Foundation |
| 2014 | Research Fellowship, Howard Hughes Medical Institute |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. MTAP Loss in Cholangiocarcinoma. Invited. Center for Cancer Epigenetics Retreat. Houston, Texas, US.
National Presentations
- 2024. MTAP-loss in Biliary Tract Cancers. Invited. Cholangiocarcinoma Foundation Annual Meetin. Salt Lake City, UT, US.
- 2023. Defining “High-Risk Resectable” Intrahepatic Cholangiocarcinoma – A Survey of the Hepatobiliary Surgical Community. Poster. Cholangiocarcinoma Summit 2023. Scottsdale, Arizona, US.
- 2023. Landscape of BRAF mutation classes in intrahepatic cholangiocarcinoma. Poster. 2023 Cholangiocarcinoma Foundation Annual Conference. Salt Lake City, Utah, US.
- 2023. Landscape of BRAF mutation classes in intrahepatic cholangiocarcinoma. Poster. 2023 ASCO Gastrointestinal Cancers Symposium, US.
- 2022. Pathogenic TP53 variant allele frequency across different somatic tissues in two patients with mosaic Li-Fraumeni. Poster. 2022 ASCO Annual Meeting, US.
- 2022. Genomic profile of intrahepatic cholangiocarcinoma with MTAP loss. Poster. 2022 ASCO Annual Meeting. Chicago, Illinois, US.
- 2022. Multidisciplinary Case-Based Discussion. Invited. 2022 Cholangiocarcinoma Foundation Annual Conference. Salt Lake City, Utah, US.
International Presentations
- 2025. Tumor vascularity as a predictor of FGFR inhibitor response in FGFR2-fused intrahepatic cholangiocarcinoma. Poster. ASCO Gastrointestinal Cancers Symposium 2025. San Francisco, US.
- 2022. 63P Intrahepatic cholangiocarcinoma (iCCA) genomic findings with high versus low tumor mutational burdens. Poster. ESMO Congress 2022, US.
- 2015. Functional evaluation of microRNA recognition elements in brain-expressed transcripts. Poster. Gordon Research Conference and Seminar: CAG Triplet Repeat Disorders. Barga, IT.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | Leveraging synthetic and collateral lethality in MTAP loss tumors |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | FP00023170 |
| Date: | 2023 - 2024 |
| Title: | MTAP Loss Clonality and Targeting in Cholangiocarcinoma |
| Funding Source: | Cholangiocarcinoma Foundation |
| Role: | PI |
| ID: | FP00018045 |
| Date: | 2020 - 2021 |
| Title: | Analysis of Mosaicism of TP53 Mutations |
| Funding Source: | Clinical Translational Science Collaborative of Cleveland |
| Role: | Co-I |
| ID: | UL1TR002548 |
| Date: | 2014 - 2015 |
| Title: | Functional evaluation of microRNA recognition elements in brain-expressed transcripts |
| Funding Source: | HHMI Medical Research Fellows |
| Role: | Co-I |
Selected Publications
Peer-Reviewed Articles
- Lim, JU, Lin, Y, Kang, L, Le, H, Tang, T, Champiat, S, Dumbrava, EE, Le, X, Naing, A, Piha-Paul, SA, Rodon Ahnert, J, Tsimberidou, AM, Yap, TA, Fu, S, Meric-Bernstam, F, Hong, DS. Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson. npj Precision Oncology 10(1), 2026. e-Pub 2026. PMID: 41530472.
- Torrado Martin, C, Andersen, C, Kang, L, Brink, AL, Adesoye, T, Le, H, Patterson, CJ, Poullard, A, Osburn, JA, Tan, HN, Gouda, M, Charles, S, Urschel, G, Tang, T, Hong, DS, Champiat, S, Naing, A, Tsimberidou, AM, Dumbrava, EE, Piha-Paul, SA, Rodon Ahnert, J, Yap, TA, Pohlmann, PR, Meric-Bernstam, F, Fu, S. Telemedicine as a gateway to early-phase oncology trials. Oncologist 31(4), 2026. e-Pub 2026. PMID: 41830429.
- Braganca Xavier C, Andersen CR, Lim J, Slade JH, Bean SA, Kang L, Le H, Tsimberidou AM, Naing A, Hong DS, Dumbrava EE, Rodon Ahnert J, Pohlmann PR, Piha-Paul SA, Champiat S, Yap TA, Tang TY, Meric-Bernstam F, Fu S. Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit. Cancer Res Commun 5(9):1631-1641, 2025. e-Pub 2025. PMID: 40862547.
- Ngoi NY, Tang TY, Gaspar CF, Pavlick DC, Buchold GM, Scholefield EL, Parimi V, Huang RS, Janovitz T, Danziger N, Levy MA, Pant S, De Armas AD, Kumpula D, Ross JS, Javle M, Ahnert JR. Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers. Oncol, 2024. e-Pub 2024. PMID: 38330461.
- Tang TY, Nichetti F, Kaplan B, Lonardi S, Pietrantonio F, Salvatore L, Vivaldi C, Rimassa L, de Braud F, Rizzato MD, Pavlick D, Chu R, Danner De Armas A, Sharaf A, Sokol E, Rodon Ahnert J, Ross JS, Javle M, Niger M. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. Clin Cancer Res, 2023. e-Pub 2023. PMID: 37773629.
- Tang TY, Cruz VB, Konczal LL. Idiopathic chronic pancreatitis treated with ivacaftor in a CFTR carrier with methylmalonic acidemia. J Cyst Fibros 21(4):603-605, 2022. e-Pub 2022. PMID: 34974990.
- Huang LF, Hong A, Cioffi G, Alahmadi A, Tang TY, Ocuin LM, Patil N, Bajor DL, Saltzman JN, Mohamed A, Selfridge E, Webb Hooper M, Barnholtz-Sloan J, Lee RT. Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After Surgery. Front Oncol 12, 2022. e-Pub 2022. PMID: 35273909.
- Tang TY, Daunov K, Lee RT. Case Report: Durable Response to Very Low Dose Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma. Front Oncol 11 - 2021, 2021. e-Pub 2021. PMID: 34976819.
- Opneja A, Cioffi G, Alahmadi A, Jones N, Tang TY, Patil N, Bajor DL, Saltzman JN, Mohamed A, Selfridge E, Mangal A, Barnholtz-Sloan J, Lee RT. Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014. Cancer Med, 2021. e-Pub 2021. PMID: 34060249.
- Ramachandran S, Coffin SL, Tang TY, Jobaliya CD, Spengler RM, Davidson BL. Cis-acting single nucleotide polymorphisms alter MicroRNA-mediated regulation of human brain-expressed transcripts. Hum Mol Genet 25(22):4939-4950, 2016. e-Pub 2016. PMID: 28171541.
Review Articles
- Almosa, R, Mendoza, MM, Tang, T, Stephen, B. Bispecific Antibodies in Solid Tumors. Journal of Immunotherapy and Precision Oncology 9(3):88-99, 2026. e-Pub 2026. PMID: 42395618.
- Derbala, M, Haymaker, CL, Morris, VK, Javle, M, How, JA, Cimo, AM, Gurses, S, Stephen, B, Tang, T, Champiat, S, Rodon Ahnert, J, Yap, TA, Dumbrava, EE, Piha-Paul, SA, Tsimberidou, AM, Fu, S, Hong, DS, Ashtamker, N, Meric-Bernstam, F, Naing, A. Biomarker study of BND-22 in combination with cemiplimab in solid tumors. Journal of Clinical Oncology 44(16):TPS2676-TPS2676, 2026. e-Pub 2026.
- Tang TY, Colbert Maresso K, Ngeow J, Vilar E, Yap TA. Germline Mutations as Cancer Drug Targets. Cancer Discov 15(11):2213-2234, 2025. e-Pub 2025. PMID: 41178351.
Abstracts
- Tang TY, Danner De Armas A, Ross JS, Pavlick D, Sharaf R, Kaplan BG, Sokol E, Rodon Ahnert J, Javle M. Landscape of BRAF mutation classes in intrahepatic cholangiocarcinoma. J Clin Oncol 41(no. 4_suppl):599-599, 2023. e-Pub 2023.
- Tang TY, Ross JS, Javle M. 63P Intrahepatic cholangiocarcinoma (iCCA) genomic findings with high versus low tumor mutational burdens. Ann Oncol 33(Supplement 7), 2022. e-Pub 2022.
- Tang TY, Ross JS, Rodon Ahnert J, Javle M. Genomic profile of intrahepatic cholangiocarcinoma with MTAP loss. J Clin Oncol 40(16 Suppl):4102-4102, 2022. e-Pub 2022.
- Tang TY, Stearns D, Miron A, Mitchell A. Pathogenic TP53 variant allele frequency across different somatic tissues in two patients with mosaic Li-Fraumeni. J Clin Oncol 40(16 suppl):10582-10582, 2022. e-Pub 2022.
Web Publications
- Javle M, Tang TY, Vogel A, Shroff R. Emerging Pathways in Advanced Cholangiocarcinoma, 2022.
Patient Reviews
CV information above last modified August 24, 2026